Oppenheimer maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $221.00 (from $228.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Alexion (ALXN) Buy On Weakness - Piper JaffrayJune 7, 2016 9:29 AM Pre-Open Stock Movers 06/07: (LDRH) (SRPT) (UNFI) Higher; (DRYS) (VRX) (MSTX) Lower (more...)June 7, 2016 9:22 AM Alexion Pharmaceuticals (ALXN) PT Lowered to $186 at Credit SuisseJune 7, 2016 8:38 AM Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMOJune 7, 2016 6:18 AM After-Hours Stock Movers 06/06: (SRPT) (UNFI) (ZG) Higher; (DRYS) (MSTX) (ALXN) Lower (more...)June 6, 2016 6:08 PM Alexion Pharma (ALXN) Sinks 9% as Trading ResumesJune 6, 2016 4:35 PM Alexion Pharma (ALXN) to Resume Trading at 4:30PM Following Trial FailureJune 6, 2016 4:14 PM Alexion Pharma (ALXN) Phase 3 REGAIN Study of Eculizumab Did Not Reach Statistical SignificanceJune 6, 2016 4:03 PM Alexion Pharma (ALXN) halted, news pendingJune 6, 2016 4:01 PM Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)June 6, 2016 4:01 PM